News and Blog
»News and Blog
Top-tier Chinese Pharmaceutical company profile: Yangtze River Pharmaceutical Group (YRPG)
Yangtze River Pharmaceutical Group (YRPG) is a large-scale Chinese pharmaceutical group who integrates research, manufacturing, and trading into a successful medical company. According to the data published by China’s Ministry of Industry and Information Technology (MIIT), YRPG took the first place in TOP 100 enterprises of the Chinese pharmaceutical industry in 2010, 2014, and 2015. It also has ranked First in the Chinese chemical-pharmaceutical industry for four consecutive years. Headquartered in Taizhou, Jiangsu Province, YRPG has over 20 subsidiaries located in Beijing, Shanghai, Nanjing, Guangzhou, etc.
Exclusive Interview | Dyadic brings biologics to the market quickly and affordably through the C1 Gene Expression Platform
The Covid-19 pandemic highlights the critical need for governments and industry to take immediate action to promote faster and more scalable manufacturing platforms, which will require developing cell lines and expression systems that markedly increase the yield of cell-based and recombinant vaccine and antibody manufacturing processes. One such promising gene expression platform is Dyadic International’s filamentous fungal, Thermothelomyces heterothallic, C1 Gene Expression Platform.
Top-tier Chinese Pharmaceutical company profile: Chia Tai Tianqing Pharmaceutical Group
CTTQ is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales and distribution capabilities. It was founded in 1969 and is headquartered in Lianyungang, Jiangsu Province, China.
Exclusive Interview | Helen Chen: Global Leader in Healthcare Consulting
Managing partner of L.E.K. Consulting Greater China, where she leads the healthcare and life sciences practice, and a director of the L.E.K. Asia Pacific Life Sciences Centre of Excellence, established in cooperation with the Singapore Economic Development Board.
Industry Research | COPD products and opportunity analysis
According to a research report by Research and Markets, the market value of COPD in 2018 was approximately US$10.9 billion, with a compound annual growth rate (CAGR) of approximately 5.9%, and it is expected to reach US$19.3 billion in 2028. Among them, the US market accounts for about 40% of the COPD market and developed regions such as Europe and Japan account for 18% and 9.2% respectively. In China, the COPD drug market has developed steadily in recent years. According to PDB data, the domestic Chinese COPD market in 2018 is was RMB 2.2 billion (approximately US$324 million). The compound growth rate reached 15.56%. The rapid growth of the COPD market is mainly due to the increasing incidence of COPD worldwide, but the cause of COPD varies by geographic region.
Industry Research | Respiratory Drugs and Products to treat Asthma and COPD
The global respiratory drug market is expected to reach US$30.7 billion in 2024.
According to EvaluatePharma’s “World Preview 2019, Outlook to 2024” report, the global prescription drug market in 2019 was US$833 billion and the compound annual growth rate (CAGR) is expected to grow by 6.9% between 2019 and 2024. By 2024, the total prescription drug market is expected to reach US$1.18 trillion.
Industry Research | Review of the latest anti-aging products from around the world
With the popularization of anti-aging treatments, for some people simple cosmetic modification is not sufficient. There is a growing preference for more permanent aesthetic medicine methods.
Frost & Sullivan data show that China has become the world’s second largest aesthetic medicine market in 2017. In 2018, the number of aesthetic medicine treatments surpassed the US, bringing China to first place.
Establishing a Foothold in the China Ophthalmology Drug and Device Market
China has a long history with ophthalmology, eye care, through traditional Chinese medicine practices, but as...
The Growth of the Pediatric Drug Market in China
As a global push for developing pediatric medicine continues, more research and clinical trials are being given the...
Top-tier Chinese Pharmaceutical company profile: Harbin Pharmaceutical Group
Harbin Pharmaceutical Group Co., Ltd. (HPGC) is a China-based Sino-foreign equity joint venture, principally engaged in pharmaceutical manufacturing, trade, and R&D. The Company’s primary products include antibiotics, small-molecule drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, and animal vaccines. The company distributes its products within domestic markets and to overseas markets.